"Company","Parent Company","Penalty Amount","Subtraction From Penalty","Penalty Amount Adjusted For Eliminating Multiple Counting","Penalty Year","Penalty Date","Offense Group","Primary Offense","Secondary Offense","Description","Level of Government","Action Type","Agency","Civil/Criminal","Prosecution Agreement","Court","Case ID","Private Litigation Case Title","Lawsuit Resolution","Facility State","City","Address","Zip","NAICS Code","NAICS Translation","HQ Country of Parent","HQ State of Parent","Ownership Structure","Parent Company Stock Ticker","Major Industry of Parent","Specific Industry of Parent","Info Source","Notes"
"Acclarent Inc.","Johnson & Johnson","$18,000,000","$0","$18,000,000","2016","20160722","government-contracting-related offenses","False Claims Act and related","","California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act",""
"Advanced Sterilization Products","Johnson & Johnson","$136,800","$0","$136,800","2014","20140520","environment-related offenses","environmental violation","","The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.","federal","agency action","Environmental Protection Agency","civil","","","","","","California","Irvine","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html",""
"Advanced Sterilization Products, a division of Ethicon Inc.","Johnson & Johnson","$1,200,000","$0","$1,200,000","2013","20131204","safety-related offenses","drug or medical equipment safety violation","","Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP's executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.","federal","agency action","Food and Drug Administration","civil","","","","","","California","Irvine","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm",""
"Johnson & Johnson","Johnson & Johnson","$2,200,000,000","$0","$2,200,000,000","2013","20131104","healthcare-related offenses","off-label or unapproved promotion of medical products","kickbacks and bribery","Global health care giant Johnson & Johnson and its subsidiaries agreed to pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by the Food and Drug Administration and payment of kickbacks to physicians and to the nation's largest long-term care pharmacy provider. The global resolution is one of the largest health care fraud settlements in U.S. history, including criminal fines and forfeiture totaling $485 million and civil settlements with the federal government and states totaling $1.72 billion.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations",""
"Johnson & Johnson","Johnson & Johnson","$48,600,000","$0","$48,600,000","2011","20110407","competition-related offenses","Foreign Corrupt Practices Act","","","federal","agency action","Securities and Exchange Commission","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.sec.gov/news/press/2011/2011-87.htm",""
"Johnson & Johnson","Johnson & Johnson","$21,400,000","$0","$21,400,000","2011","20110408","competition-related offenses","Foreign Corrupt Practices Act","","Johnson & Johnson agreed to pay a $21.4 million criminal penalty as part of a deferred prosecution agreement with the Department of Justice to resolve charges of improper payments by J&J subsidiaries to government officials in Greece, Poland and Romania in violation of the Foreign Corrupt Practices Act.","federal","agency action","Justice Department Criminal Division","criminal","deferred prosecution agreement","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/johnson-johnson-agrees-pay-214-million-criminal-penalty-resolve-foreign-corrupt-practices-act",""
"Johnson & Johnson Medical, Inc.","Johnson & Johnson","$3,900,000","$0","$3,900,000","2001","20010921","government-contracting-related offenses","False Claims Act and related","","Johnson & Johnson Medical, Inc. agreed to pay $3.9 million to settle allegations that it overcharged the Veterans Administration for medical supplies.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2001/September/488civ.htm",""
"Lifescan, Inc.","Johnson & Johnson","$15,000,000","$0","$15,000,000","2001","20011114","government-contracting-related offenses","False Claims Act and related","","Lifescan, Inc. agreed to pay $15 million to resolve allegations that it failed to notify the Veterans Administration that it had reduced prices to certain commercial customers below the cost negotiated by the agency. As a result, the VA, and other federal agencies purchasing through the contract, were overcharged.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2001/November/01_civ_590.htm",""
"McNeil-PPC Inc.","Johnson & Johnson","$25,000,000","$0","$25,000,000","2015","20150310","safety-related offenses","drug or medical equipment safety violation","","McNeil-PPC Inc. entered a guilty plea in Federal District Court in Philadelphia to one count of an information charging the company with delivering for introduction into interstate commerce adulterated infants' and childrens' over-the-counter liquid medicines. As part of the criminal resolution, McNeil, a wholly owned subsidiary of Johnson & Johnson, agreed to pay a criminal fine of $20 million and forfeit $5 million.","federal","agency action","Food and Drug Administration referral to the Justice Department","criminal","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/mcneil-ppc-inc-pleads-guilty-connection-adulterated-infants-and-childrens-over-counter-liquid",""
"Micrus Corporation","Johnson & Johnson","$450,000","$0","$450,000","2005","20050302","competition-related offenses","Foreign Corrupt Practices Act","","Micrus Corporation--a privately held company based in Sunnyvale, California that develops and sells, in domestic and foreign markets, medical devices known as embolic coils which allow minimally invasive treatment of neurovascular diseases such as intracranial aneurysms--agreed to resolve its criminal liability associated with potential violations of the Foreign Corrupt Practices Act by paying $450,000 in penalties to the United States and cooperating fully with an investigation by the Department of Justice.","federal","agency action","Justice Department Criminal Division","criminal","non-prosecution agreement","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2005/March/05_crm_090.htm",""
"Ortho McNeil Pharmaceutical","Johnson & Johnson","$3,400,000","$0","$3,400,000","2009","20091019","government-contracting-related offenses","False Claims Act and related","","Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid",""
"Ortho-McNeil Pharmaceutical LLC","Johnson & Johnson","$81,000,000","$0","$81,000,000","2010","20100429","healthcare-related offenses","off-label or unapproved promotion of medical products","","American pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., both subsidiaries of Johnson & Johnson, agreed to pay more than $81 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Topamax.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/two-johnson-johnson-subsidiaries-pay-over-81-million-resolve-allegations-label-promotion",""
"Scios Inc.","Johnson & Johnson","$85,000,000","$0","$85,000,000","2011","20111005","healthcare-related offenses","off-label or unapproved promotion of medical products","","Scios Inc., a subsidiary of pharmaceutical giant Johnson & Johnson, pleaded guilty to a misdemeanor violation of the Food, Drug and Cosmetic Act for introducing into interstate commerce its heart failure drug, Natrecor, for a use that was not approved by the Food and Drug Administration, the Justice Department announced. The district court also sentenced Scios, based in Fremont, Calif., to pay an $85 million criminal fine in accordance with the plea agreement between Scios and the United States.","federal","agency action","Food and Drug Administration referral to the Justice Department","criminal","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/johnson-johnson-subsidiary-scios-pleads-guilty-misbranding-heart-failure-drug-natrecor",""
"STERILMED, INC.","Johnson & Johnson","$11,278","$0","$11,278","2006","20060629","safety-related offenses","workplace safety or health violation","","","federal","agency action","Occupational Safety & Health Administration","civil","","","","","","Georgia","CUMMING","767 PEACHTREE PKWY., STE. 4","30130","811219","811219: Other Electronic and Precision Equipment Repair and Maintenance","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","Extracted from a download of OSHA's Enforcment Data downloaded on 3/02/2022, available at https://enforcedata.dol.gov/views/data_catalogs.php",""
"Janssen Pharmaceuticals, Inc.","Johnson & Johnson","$410,000,000","$0","$410,000,000","2013","20130103","healthcare-related offenses","off-label or unapproved promotion of medical products","","Janssen Pharmaceuticals pleaded guilty to a charge of introducing a misbranded drug, Risperdal, into interstate commerce and was ordered to pay a $344 million fine and forfeiture of $66 million.","federal","agency action","U.S. Attorney-Eastern District of Pennsylvania","criminal","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/usao-edpa/pr/janssen-pharmaceuticals-pleads-guilty-and-sentenced-misbranding",""
"Synthes Inc.","Johnson & Johnson","$669,800","$0","$669,800","2010","20101004","safety-related offenses","drug or medical equipment safety violation","","","federal","agency action","U.S. Attorney-Eastern District of Pennsylvania","criminal","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/usao/pae/News/2010/Oct/synthes,norian_release.pdf",""
"Ortho-McNeil Pharmaceutical LLC","Johnson & Johnson","$6,140,000","$0","$6,140,000","2010","20100521","safety-related offenses","drug or medical equipment safety violation","","Ortho-McNeil Pharmaceutical LLC, a subsidiary of Johnson & Johnson, pled guilty in U.S. District Court in Boston to one count of misdemeanor violation of the Food, Drug & Cosmetic Act for illegally promoting its epilepsy drug Topamax for uses that were not approved by the FDA.","federal","agency action","U.S. Attorney-District of Massachusetts","criminal","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/usao/ma/news/2010/May/OrthoMcNeilSentencingPR.html",""
"Johnson & Johnson","Johnson & Johnson","$511,000","$0","$511,000","2008","20080805","healthcare-related offenses","Controlled Substances Act violation","","","federal","agency action","U.S. Attorney-Eastern District of Pennsylvania","civil","","","","","","Pennsylvania","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/usao/pae/News/2008/aug/warnerrelease.pdf",""
"Depuy Orthopaedics Inc.","Johnson & Johnson","$84,700,000","$0","$84,700,000","2007","20070927","government-contracting-related offenses","False Claims Act and related","kickbacks and bribery","Five companies that account for nearly 95 percent of the lucrative market in hip and knee surgical implants avoided criminal prosecution over financial inducements paid to surgeons to use their products by paying settlements and agreeing to new corporate compliance procedures and federal monitoring under 18-month agreements with the Department of Justice.","federal","agency action","U.S. Attorney-District of New Jersey","civil and criminal","deferred prosecution agreement","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/usao/nj/Press/files/pdffiles/Older/hips0927.rel.pdf",""
"ETHICON ENDO SURGERY","Johnson & Johnson","$5,500","$0","$5,500","2010","20100421","safety-related offenses","aviation safety violation","","hazardous materials shipping","federal","agency action","Federal Aviation Administration","civil","","","2009GL700325","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","from a spreadsheet posted on the FAA website at https://www.faa.gov/about/office_org/headquarters_offices/ash/ash_programs/hazmat/compliance_enforcement/",""
"Synthes USA","Johnson & Johnson","$5,000,000","$0","$5,000,000","2016","20161220","employment-related offenses","wage and hour violation","","","federal","private litigation","","civil","","Eastern District of California","11-cv-02053","Lindell et al v. Synthes USA et al","settlement","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.bigclassaction.com/settlement/j-j-subsidiary-synthes-settles-employment-class.php",""
"Actelion Pharmaceuticals US, Inc.","Johnson & Johnson","$360,000,000","$0","$360,000,000","2018","20181206","government-contracting-related offenses","False Claims Act and related","kickbacks and bribery","Pharmaceutical company Actelion Pharmaceuticals US, Inc. agreed to pay $360 million to resolve claims that it illegally used a foundation as a conduit to pay the copays of thousands of Medicare patients taking Actelion's pulmonary arterial hypertension drugs, in violation of the False Claims Act.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/drug-maker-actelion-agrees-pay-360-million-resolve-false-claims-act-liability-paying",""
"LifeScan Inc.","Johnson & Johnson","$60,000,000","$0","$60,000,000","2000","20001215","safety-related offenses","drug or medical equipment safety violation","","LifeScan, a subsidiary of Johnson & Johnson, pled guilty to criminal charges and agreed to pay $60 million in fines for selling defective blood glucose monitoring devices to diabetics and submitting false information about the problems to federal regulators.","federal","agency action","U.S. Attorney-Northern District of California","criminal","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.nytimes.com/2000/12/16/business/guilty-plea-by-division-of-drug-giant.html",""
"DePuy Orthopaedics Inc.","Johnson & Johnson","$4,000,000","$0","$4,000,000","2014","20140702","safety-related offenses","drug or medical equipment safety violation","","DePuy paid $4 million to resolve allegations that it failed to disclose to physicians and patients that its ASR XL metal-on-metal artificial hip devices had a high rate of failure.","state","agency action","Oregon Attorney General","civil","","","","","","Oregon","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.doj.state.or.us/media-home/news-media-releases/oregon-settles-with-artificial-hip-manufacturer-depuy-for-4-million/",""
"Janssen Ortho LLC and Janssen Pharmaceuticals, Inc.","Johnson & Johnson","$5,900,000","$0","$5,900,000","2014","20140306","healthcare-related offenses","off-label or unapproved promotion of medical products","","Janssen agreed to pay $5.9 million in settlement of allegations it marketed its antipsychotic drug Risperdal for unapproved uses and hid dangers associated with the drug.","state","agency action","Montana Attorney General","civil","","","","","","Montana","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20190702210633/https://dojmt.gov/attorney-general-fox-announces-5-9-million-pharmaceutical-settlement-launches-new-rx-drug-abuse-prevention-program/#more-31589",""
"Janssen Pharmaceutical Products, LP, Centocor, Inc., McNeil Pharmaceutical, Inc., Ortho Biotech Products, LP and Ortho-McNeil Pharmaceutical, Inc.","Johnson & Johnson","$7,000,000","$0","$7,000,000","2012","20120613","government-contracting-related offenses","False Claims Act and related","","The Johnson & Johnson family of companies, encompassing Janssen Pharmaceutical Products, LP, Centocor, Inc., McNeil Pharmaceutical, Inc., Ortho Biotech Products, LP and Ortho-McNeil Pharmaceutical, Inc. agreed to pay $7 million in settlement of alleged improper reporting of the average wholesale price of its drugs, causing Medicaid to overpay.","state","agency action","Kentucky Attorney General","civil","","","","","","Kentucky","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20121130065001/http://migration.kentucky.gov/Newsroom/ag/johnsonawpsettlement.htm",""
"Janssen Pharmaceuticals, Inc.","Johnson & Johnson","$181,000,000","$0","$181,000,000","2012","20120830","healthcare-related offenses","off-label or unapproved promotion of medical products","","Janssen Pharmaceuticals, Inc. and its parent company Johnson & Johnson agreed to pay $181 million to resolve multistate litigation alleging improper marketing and advertising of the powerful anti-psychotic drugs Risperdal and Invega. ","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20161130182211/http://ag.ny.gov/press-release/ag-schneiderman-settles-181-million-deceptive-marketing-case-janssen-pharmaceuticals/",""
"Janssen Pharmaceuticals, Inc.","Johnson & Johnson","$15,100,000","$0","$15,100,000","2013","20131104","healthcare-related offenses","off-label or unapproved promotion of medical products","kickbacks and bribery","Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, agreed to pay $15.1 million in settlement of allegations it violated consumer protection laws in promoting Risperdal. This was at the same time as two other settlements, one federal and state, and one multistate, relating to allegations that the company engaged in illegal marketing and making improper payments to providers. ","state","agency action","Massachusetts Attorney General","civil","","","","","","Massachusetts","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20131210003242/http://www.mass.gov/ago/news-and-updates/press-releases/2013/2013-11-04-johnson-johnson-settlement.html",""
"Johnson & Johnson","Johnson & Johnson","$120,000,000","$0","$120,000,000","2019","20190122","safety-related offenses","drug or medical equipment safety violation","","Johnson & Johnson and several of its subsidiaries jointly agreed to pay $120 million to resolve multistate litigation alleging they unlawfully promoted metal-on-metal hip implant devices, the ASR XL and the Pinnacle Ultamet, by making misleading claims about their longevity, also known as survivorship.","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.oag.ca.gov/news/press-releases/attorney-general-becerra-announces-120-million-settlement-against-johnson",""
"Johnson & Johnson","Johnson & Johnson","$33,000,000","$0","$33,000,000","2017","20170524","safety-related offenses","drug or medical equipment safety violation","consumer protection violation","Johnson & Johnson agreed to pay $33 million as part of the settlement of multistate litigation allegations that the company's subsidiary, McNeil-PPC, Inc., employed deceptive practices to market and promote numerous popular over-the-counter drugs.","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20190831170301/https://ag.ny.gov/press-release/ag-schneiderman-announces-33-million-multi-state-settlement-johnson-johnson-end",""
"Johnson & Johnson","Johnson & Johnson","$541,000,000","$541,000,000","$0","2013","20131104","healthcare-related offenses","off-label or unapproved promotion of medical products","kickbacks and bribery","Johnson & Johnson and its subsidiaries agreed to pay $541 million to resolve multistate litigation alleging unlawful marketing practices, including off-label promotion and kickbacks, to promote the sales of their atypical antipsychotic drugs, Risperdal and Invega. The off-label marketing accounted for $524 million; the other $17 million resolved allegations that J&J subsidiary Janssen paid kickbacks to nuring home pharmacy Omnicare. All of this was part of a larger $2.2 billion civil and criminal settlement involving the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-johnson-and-johnson","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations",""
"Johnson & Johnson","Johnson & Johnson","$158,000,000","$0","$158,000,000","2012","20120119","healthcare-related offenses","off-label or unapproved promotion of medical products","False Claims Act and related","Johnson & Johnson and its subsidiary Janssen agreed to pay $158 million to settle allegations that it improperly urged physicians to prescribe the drug Risperdal to children and the elderly for schizophrenia and dementia, despite the fact that the drug had not been approved by the U.S. Food and Drug Administration for these uses at the time. ","state","agency action","Texas Attorney General","civil","","","","","","Texas","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","Texas Attorney General Secures $158 Million Agreement with Drug Maker Over Medicaid Fraud Allegations, Targeted News Service, January 19, 2012 (via Nexis).",""
"Johnson & Johnson","Johnson & Johnson","$9,900,000","$0","$9,900,000","2019","20190422","safety-related offenses","drug or medical equipment safety violation","","Johnson & Johnson agreed to pay $9.9 million to asettle allegations of misrepresentations and failure to include serious risks in the instructions and marketing materials for surgical mesh devices.","state","agency action","Washington Attorney General","civil","","","","","","Washington","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.atg.wa.gov/news/news-releases/johnson-johnson-will-pay-99-million-failing-disclose-risk-its-surgical-mesh",""
"Johnson & Johnson","Johnson & Johnson","$10,000,000","$0","$10,000,000","2013","20131118","government-contracting-related offenses","False Claims Act and related","","The Louisiana Attorney General's Office announced that it had obtained a total of $88 million in settlements from 25 pharmaceutical companies to resolve allegations they overcharged the state's Medicaid program.","state","agency action","Louisiana Attorney General","civil","","","","","","Louisiana","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20131206104321/http://www.ag.state.la.us/Article.aspx?articleID=788&catID=2",""
"Johnson & Johnson et al.","Johnson & Johnson","$5,200,000","$0","$5,200,000","2010","20101006","government-contracting-related offenses","False Claims Act and related","","Johnson & Johnson and several of its subsidiaries agreed to pay $5.2 million as part of a series of settlements between pharmaceutical companies and Hawaii of allegations that they published inflated prices for drugs and thus increased Medicaid costs.","state","agency action","Hawaii Attorney General","civil","","","","","","Hawaii","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","http://ag.hawaii.gov/wp-content/uploads/2012/12/2010-21.pdf",""
"Johnson & Johnson Vision Care, Inc.","Johnson & Johnson","$60,000,000","$0","$60,000,000","2001","20010522","competition-related offenses","price-fixing or anti-competitive practices","","To settle a multistate antitrust action, Johnson & Johnson agreed to provide at least $30 million in customer rebates, pay $25 million into a settlement fund and provide $5 million in cash and coupons to former customers.","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.oag.ca.gov/news/press-releases/attorney-general-lockyer-announces-settlement-contact-lens-antitrust-lawsuit",""
"Johnson & Johnson, Janssen Pharmaceutical Products LP, Ortho-McNeil Pharmaceutical, Inc., Ortho Biotech Products, LP, McNeil-PPC, Inc. and Centocor, I","Johnson & Johnson","$2,000,000","$0","$2,000,000","2011","20111206","government-contracting-related offenses","False Claims Act and related","","Johnson & Johnson and its subsidiaries  Janssen Pharmaceutical Products LP, Ortho-McNeil Pharmaceutical, Inc., Ortho Biotech Products, LP, McNeil-PPC, Inc. and Centocor, Inc. agreed to pay a total of $2 million in settlement of allegations  they misreported the average wholesale price of their drugs.","state","agency action","Idaho Attorney General","civil","","","","","","Idaho","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20120513203747/http://www.ag.idaho.gov/media/newsReleases/2011/nr_12062011.html",""
"Johnson and Johnson","Johnson & Johnson","$4,475,000","$0","$4,475,000","2009","20090302","consumer-protection-related offenses","consumer protection violation","","A Brooke County Circuit Judge ordered Johnson and Johnson and its Janssen Pharmaceutica subsidiary to pay civil penalties totaling $4,475,000 for making false or misleading statements to West Virginia physicians about two of its products, Risperdal, an antipsychotic drug, and Duragesic, a narcotic pain patch.","state","agency action","West Virginia Attorney General","civil","","","","","","West Virginia","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","Court Orders Johnson and Johnson to Pay Millions for Misleading WV Doctors, States News Service, March 2, 2009 (via Nexis).",""
"LifeScan, Inc.","Johnson & Johnson","$30,600,000","$0","$30,600,000","2003","20030411","safety-related offenses","drug or medical equipment safety violation","False Claims Act and related","LifeScan, a subsidiary of Johnson & Johnson, agreed to pay $30.6 million to 46 states, the District of Columbia and the federal government to settle civil litigation alleging that it sold adulterated and misbranded glucose monitoring systems, some of which were paid for by government healthcare programs. Separately, the company paid a criminal fine of $29.4 million, which is shown in a Justice Department entry. ","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20040217222513/http://www.doj.state.wi.us/news/nr041103_MDFr.asp",""
"McNeil-PPC Inc.","Johnson & Johnson","$500,000","$0","$500,000","2015","20150729","consumer-protection-related offenses","consumer protection violation","","McNeil-PPC Inc., a subsidiary of Johnson and Johnson, paid $500,000 to settle claims concerning a ""phantom recall"" of Children's Motrin that the company allegedly conducted in 2009. It was reported that certain lots of the drug were found to be substandard, and that instead of conducting an open recall, the company sent teams of people to surreptitiously buy and remove all of the product remaining in stores. ","state","agency action","Alabama Attorney General","civil","","","","","","Alabama","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://ago.alabama.gov/documents/news/686.pdf",""
"McNeil-PPC, Inc.","Johnson & Johnson","$52,000","$0","$52,000","2004","20040910","consumer-protection-related offenses","consumer protection violation","","","state","agency action","New York Attorney General","civil","","","","","","New York","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20101119014842/http://www.ag.ny.gov/media_center/2004/sep/sep10a_04.html",""
"Ortho-McNeil Pharmaceutical LLC","Johnson & Johnson","$24,681,516","$24,681,516","$0","2010","20100429","healthcare-related offenses","off-label or unapproved promotion of medical products","","Pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., both subsidiaries of Johnson & Johnson, agreed to pay more than $24 million to settle multistate litigation alleging they promoted the epilepsy drug Topamax for uses not approved by the Food and Drug Administration. This was part of a larger $81 million civil and criminal settlement involving the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-ortho-mcneil-pharmaceutical-llc","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/two-johnson-johnson-subsidiaries-pay-over-81-million-resolve-allegations-label-promotion",""
"Ortho-McNeil Pharmaceutical, Inc.","Johnson & Johnson","$3,400,000","$3,400,000","$0","2009","20091019","government-contracting-related offenses","False Claims Act and related","","Ortho-McNeil agreed to pay $3.4 million to settle multistate litigation claiming it violated the False Claims Act by failing to pay appropriate rebates for drugs that were paid for by Medicaid. Also involved in the settlement was the U.S. Justice Department, which made its own announcement; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-ortho-mcneil-pharmaceutical","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20100213182921/http://www.ag.ny.gov/media_center/2009/oct/oct19a_09.html",""
"Synthes, Inc.","Johnson & Johnson","$236,000","$0","$236,000","2009","20090505","consumer-protection-related offenses","consumer protection violation","","failure to disclose financial conflicts-of-interest among doctors who conducted clinical testing on medical devices","state","agency action","New Jersey Attorney General","civil","","","","","","New Jersey","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.nj.gov/oag/newsreleases09/pr20090505a.html",""
"Johnson & Johnson","Johnson & Johnson","$49,505,368","$0","$49,505,368","2019","20191028","government-contracting-related offenses","False Claims Act and related","","The Illinois Attorney General Kwame announced the recovery of $242 million in a settlement with numerous drug companies resolving allegations the companies inflated the wholesale prices used in setting the rates for Medicaid reimbursements.","state","agency action","Illinois Attorney General","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","http://www.illinoisattorneygeneral.gov/pressroom/2019_10/20191028.html",""
"Johnson & Johnson","Johnson & Johnson","$116,860,000","$0","$116,860,000","2019","20191017","safety-related offenses","drug or medical equipment safety violation","","Johnson & Johnson and its subsidiary Ethicon, Inc. agreed to pay over $116 million to 41 states and the District of Columbia to settle litigation alleging deceptive marketing of transvaginal surgical mesh devices.","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","http://www.law.state.ak.us/press/releases/2019/101719-JohnsonJohnson.html",""
"Johnson & Johnson","Johnson & Johnson","$506,000","$0","$506,000","2015","20150114","consumer-protection-related offenses","consumer protection violation","","Johnson & Johnson agreed to pay $506,000 to the District Attorneys of Fresno, San Joaquin, Shasta and Yolo counties to resolve allegations that packaging for Neutrogena and other products was misleading.","local","agency action","California Multi-Jurisdiction Case","civil","","","","","settlement","California","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","DA offices settle product packaging case, The Davis Enterprise, January 14, 2015 (via Nexis).",""
"Johnson & Johnson","Johnson & Johnson","$3,900,000","$0","$3,900,000","2020","20200504","safety-related offenses","drug or medical equipment safety violation","","The State of West Virginia reached a $3.9 million settlement with Johnson & Johnson regarding the marketing of surgical mesh devices and hip replacement systems.","state","agency action","West Virginia Attorney General","civil","","","","","","West Virginia","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.wvgazettemail.com/news/legal_affairs/wv-settles-pelvic-mesh-hip-device-lawsuit-with-johnson-johnson-for-3-9m/article_7e769d78-2ac0-5923-bbbe-0f965798b2db.html",""
"Advanced Sterilization Products","Johnson & Johnson","$25,616","$0","$25,616","2012","20121120","environment-related offenses","environmental violation","","pesticide violation","state","agency action","California Department of Pesticide Regulation","civil","","","","","","California","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","Contained in data obtained from the agency on October 6, 2020 in response to an open records request. ",""
"Neutrogena Corp.","Johnson & Johnson","$416,248","$0","$416,248","2014","20141124","environment-related offenses","environmental violation","","Neutrogena agreed to pay a $416,248 civil penalty in settlement of allegations it treated hazardous waste without a permit, disposed of hazardous waste in normal waste, and failed to properly manage hazardous waste or comply with regulations.","state","agency action","California Department of Toxic Substances Control","civil","","","","","","California","Los Angeles","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://dtsc.ca.gov/2014/12/18/neutrogena-fined-for-hazardous-waste/",""
"ETHICON INC","Johnson & Johnson","$5,250","$0","$5,250","2009","20091224","environment-related offenses","environmental violation","","air quality violation","state","agency action","New Jersey Department of Environmental Protection","civil","","","35041-NEA090001","","","New Jersey","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","Contained in data received from the agency on October 26, 2020 in response to an open records request. The data was a spreadsheet version of information contained in the records in the DEP DataMiner at https://www13.state.nj.us/DataMiner",""
"Johnson & Johnson","Johnson & Johnson","$5,000,000,000","$0","$5,000,000,000","2021","20210721","healthcare-related offenses","off-label or unapproved promotion of medical products","","Johnson & Johnson, the parent company of Janssen Pharmaceuticals, reached an agreement with a group of states under which it would pay $5 billion to resolve Janssen's involvement in litigation alleging improper sale of pain medications, contributing to the national opioid epidemic.","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://ncdoj.gov/attorney-general-josh-stein-announces-26-billion-agreement-with-opioid-distributors-manufacturer/",""
"Johnson & Johnson","Johnson & Johnson","$2,500,000,000","$0","$2,500,000,000","2021","20210601","safety-related offenses","product safety violation","","In 2018 a Missouri state jury awarded $4 billion in damages to a group of women who claimed they developed ovarian cancer from using Johnson & Johnson's talcum powder. A state appeals court reduced the award to $2.1 billion. That award was upheld by the Missouri Supreme Court. After the U.S. Supreme Court refused to hear J&J appeal, the company paid the award plus interest, reporting the total as $2.5 billion.","federal","private litigation","","civil","","St. Louis City (Missouri) Circuit Court","","Ingham v. Johnson & Johnson et al.","verdict","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.sec.gov/ix?doc=/Archives/edgar/data/200406/000020040621000070/jnj-20211003.htm",""
"Janssen Pharmaceuticals","Johnson & Johnson","$387,500,000","$0","$387,500,000","2019","20190325","safety-related offenses","drug or medical equipment safety violation","product safety violation","Bayer and Janssen Pharmaceuticals agreed to split a $775 million multi-district settlement with thousands of plaintiffs who alleged that the companies failed to warn about bleeding risks associated with the blood thinner Xarelto.","federal","private litigation","","civil","","Eastern District of Louisiana","2:14-md-02592","In Re: Xarelto (Rivaroxaban) Products Liability Litigation","settlement","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.law360.com/articles/1142309/bayer-janssen-pay-775m-to-end-xarelto-suits",""
"DePuy Orthopaedics, Inc.","Johnson & Johnson","$2,475,000,000","$0","$2,475,000,000","2013","20131119","safety-related offenses","drug or medical equipment safety violation","product safety violation","DePuy Orthopaedics, a subsidiary of Johnson & Johnson, agreed to pay more than $2 billion to settle multi-district litigation relating to faulty hip implants.","federal","private litigation","","civil","","Northern District of Ohio","1:10md2197","ASR Hip Implant Products Liability Litigation","settlement","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","http://www.nytimes.com/2013/11/20/business/johnson-johnson-to-offer-2-5-billion-hip-device-settlement.html?_r=0",""
"Johnson & Johnson","Johnson & Johnson","$15,000,000","$0","$15,000,000","2005","20051215","safety-related offenses","drug or medical equipment safety violation","product safety violation","Johnson & Johnson agreed to pay up to $15 million to settle a second round of multi-district litigation alleging that its heartburn drug Propulsid caused cardiac problems.","federal","private litigation","","civil","","Eastern District of Louisiana","2:00md1355","In Re: Propulsid Prod V.","settlement","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.law360.com/articles/30570/propulsid-suits-dismissed-as-case-draws-to-a-close",""
"Johnson & Johnson","Johnson & Johnson","$90,000,000","$0","$90,000,000","2004","20040130","safety-related offenses","drug or medical equipment safety violation","product safety violation","Johnson & Johnson agreed to pay up to $90 million to settle multi-district litigation alleging that its heartburn drug Propulsid caused cardiac problems.","federal","private litigation","","civil","","Eastern District of Louisiana","2:00md1355","In Re: Propulsid Prod V.","settlement","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://pink.pharmaintelligence.informa.com/PS043304/JampJ-agrees-to-Propulsid-settlement",""
"Johnson & Johnson","Johnson & Johnson","$45,000,000","$0","$45,000,000","2002","20020318","safety-related offenses","drug or medical equipment safety violation","product safety violation","Johnson & Johnson unit Lifescan Inc. agreed to pay $45 million to settle class action litigation that its blood sugar meters were defective.","federal","private litigation","","civil","","Northern District of California","5:98cv20321","In Re Lifescan, Inc.","settlement","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","https://www.nytimes.com/2001/11/28/business/company-news-johnson-johnson-unit-will-pay-45-million-settlement.html",""
"ETHICON, INC.","Johnson & Johnson","$6,518","$0","$6,518","2017","20170503","safety-related offenses","workplace safety or health violation","","","federal","agency action","Occupational Safety & Health Administration","civil","","","","","","Texas","SAN ANGELO","3348 PULLIAM ST","76905","339112","339112: Surgical and Medical Instrument Manufacturing","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","Extracted from a download of OSHA's Enforcment Data downloaded on 3/02/2022, available at https://enforcedata.dol.gov/views/data_catalogs.php",""
"JOHNSON & JOHNSON CONSUMER, INC.","Johnson & Johnson","$7,853","$0","$7,853","2018","20180705","safety-related offenses","workplace safety or health violation","","","federal","agency action","Occupational Safety & Health Administration","civil","","","","","","Pennsylvania","FORT WASHINGTON","7050 CAMP HILL ROAD","19034","325412","325412: Pharmaceutical Preparation Manufacturing","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","Extracted from a download of OSHA's Enforcment Data downloaded on 3/02/2022, available at https://enforcedata.dol.gov/views/data_catalogs.php",""
"ETHICON, INC.","Johnson & Johnson","$9,832","$0","$9,832","2020","20200428","safety-related offenses","workplace safety or health violation","","","federal","agency action","Occupational Safety & Health Administration","civil","","","","","","Texas","SAN ANGELO","3348 PULLIAM ST","76905","339112","339112: Surgical and Medical Instrument Manufacturing","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","Extracted from a download of OSHA's Enforcment Data downloaded on 3/02/2022, available at https://enforcedata.dol.gov/views/data_catalogs.php",""
"Janssen Pharmaceutical (SB)","Johnson & Johnson","$105,000","$0","$105,000","2010","20100917","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","02-2010-5108","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads",""
"Advanced Sterilization Products, Div of Ethicon","Johnson & Johnson","$136,800","$136,800","$0","2014","20140516","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","09-2014-4006","","","California","IRVINE","33 TECHNOLOGY DRIVE","92618-2346","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads","Note: This penalty is a duplicate of an amount shown in another record (either because it applies to a multi-location settlement or because Violation Tracker contains an agency record and a settlement announcement for the same case)."
"Janssen Pharmaceutica Inc.","Johnson & Johnson","$7,700","$0","$7,700","2004","20040205","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","10-2004-0016","","","","","","","","","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads",""
"Johnson & Johnson","Johnson & Johnson","$5,000","$0","$5,000","2004","20040831","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","HQ-2004-0023","","","California","VACAVILLE","700 EUBANKS DRIVE","95688","325412","325412: Pharmaceutical Preparation Manufacturing","USA","New Jersey","publicly traded","JNJ","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads",""
